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Systems analysis of avascular 
necrosis of femoral head using 
integrative data analysis 
and literature mining delineates 
pathways associated with disease
Ashwin Ashok Naik1,5, Aswath Narayanan1,5, Prakash Khanchandani2*, Divya Sridharan3, 
Piruthivi Sukumar4, Sai Krishna Srimadh Bhagavatam1, Polani B. Seshagiri3 & 
Venketesh Sivaramakrishnan1*
Avascular necrosis of femoral head (AVNFH) is a debilitating disease, which affects the middle 
aged population. Though the disease is managed using bisphosphonate, it eventually leads to 
total hip replacement due to collapse of femoral head. Studies regarding the association of single 
nucleotide polymorphisms with AVNFH, transcriptomics, proteomics, metabolomics, biophysical, 
ultrastructural and histopathology have been carried out. Functional validation of SNPs was carried 
out using literature. An integrated systems analysis using the available datasets might help to gain 
further insights into the disease process. We have carried out an analysis of transcriptomic data 
from GEO-database, SNPs associated with AVNFH, proteomic and metabolomic data collected from 
literature. Based on deficiency of vitamins in AVNFH, an enzyme-cofactor network was generated. 
The datasets are analyzed using ClueGO and the genes are binned into pathways. Metabolomic 
datasets are analyzed using MetaboAnalyst. Centrality analysis using CytoNCA on the data sets 
showed cystathionine beta synthase and methylmalonyl-CoA-mutase to be common to 3 out of 4 
datasets. Further, the genes common to at least two data sets were analyzed using DisGeNET, which 
showed their involvement with various diseases, most of which were risk factors associated with 
AVNFH. Our analysis shows elevated homocysteine, hypoxia, coagulation, Osteoclast differentiation 
and endochondral ossification as the major pathways associated with disease which correlated with 
histopathology, IHC, MRI, Micro-Raman spectroscopy etc. The analysis shows AVNFH to be a multi-
systemic disease and provides molecular signatures that are characteristic to the disease process.
Avascular Necrosis of Femoral Head (AVNFH) is a debilitating disease, usually affecting younger individu-
als. Clinically AVNFH is associated with reduction in vascular supply to the subchondral bone of the femo-
ral head which leads to necrosis and collapse of articular surface and eventual degeneration of hip  joint1–3. 
AVNFH has been categorized basically into idiopathic and secondary varieties. The secondary causes of AVNFH 
include haemoglobinopathies, storage disorders, SLE, decompression sickness etc.4,5 alcohol, Steroid, trauma, 
 coagulopathies6,7 Numerous other factors like genetic factors, environmental factors, physiological process like 
pregnancy, lifestyle involving smoking, drug abuse, diseases like haemochromatosis have also been implicated 
as risk factors in  AVNFH8–10.
Biophysical characterization of bone from AVNFH patients and piglet model of disease shows reduced 
mineral to matrix ratio and increased carbonate to phosphate ratio indicative of extensive remodelling due 
to osteoclast  activity1,11. Histopathology shows increased cement lines and lacunae while electron microscopy 
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shows micro-cracks, dead bone and woven bone  substitution1. Immuno histochemistry of AVNFH bone shows 
increased  osteocalcein1,  iNOS12,  RANKL13, BMP-2 and HIF-1  staining14,15. AVNFH is also associated with 
coagulation disorders and coagulopathies possibly play an important role in the pathophysiology of the disease. 
Consistent with this, increased microparticles have been observed in the blood of AVNFH patients which might 
clog capillaries and contribute to  avascularity14–17. High amounts of Von Willebrand Factor which is associated 
with AVNFH will also lead to  thrombosis18. Coagulation factor disorders have been correlated with  AVNFH19. 
Endochondral ossification, where cartilage is replaced by bone was also shown to be inhibited in  AVNFH20. 
These studies point to a complex association of hypoxia, thrombosis, reduced osteoblast activity and increased 
osteoclast activity in the pathogenesis of AVNFH.
More so, AVNFH has now been considered as a Multi systemic disease rather than as a disease involv-
ing just the femoral  head4. The genetic factors include mutations in Col2A2, MTHFR, NOS, PAI-1, PON-1, 
alpha-2-Microglobulin, SREBP-2, VEGFC, ADH-2, and sometimes associated with Increased Lipoprotein A and 
protein C  deficiency21. However, MTHFR mutations do not correlate with the disease in Korean and Japanese 
 populations22, pointing to a possible population specific differences.
Omic techniques like transcriptomic, proteomic or metabolomics analysis of serum or tissues from AVNFH 
patients or model systems have been carried  out23–26. The transcriptomic and proteomic analysis have largely 
reiterated on the signalling pathways that are deregulated in  AVNFH24,26. These pathways are largely binned 
into osteoclastogenesis, osteoblasts and their function etc. Microarray studies have been carried out using rat 
models of steroid induced AVNFH and cartilage from diseased area of human AVNFH  patients27. The results 
show deregulation of key pathways involved in the pathogenesis of AVNFH. Microarray analysis of whole tran-
scriptome of AVNFH articular cartilage was performed at different time points from the induction of ischemic 
injury and compared to  control24. The study showed genes involved in ischemic injury and angiogenesis were 
significantly upregulated at 2 weeks post AVNFH onset and those belonging to the inflammatory pathway four 
weeks post onset of the disease. Proteomic studies have also been carried out on AVNFH patient bone  samples28. 
These studies points to deregulation of multiple signalling and metabolic pathways which are implicated in 
cartilage and bone biology. Targeted metabolomic analysis shows elevated levels of metabolites belonging to 
Methionine–Homocysteine pathway, Polyamine and urea pathway concomitant with low levels of  B12,  B6 and 
Betaine in AVNFH  patients1. Metabolomic analysis of bone tissue in Chinese population showed changes in 
amino-acid and fatty acid  metabolism25. Serum metabolomic analysis of rabbit model of steroid induced AVNFH 
showed differentially regulated  phospholipids29. These studies show perturbations in different signalling and 
metabolic pathways in AVNFH.
However, a concerted effort to analyse the disease from a systems perspective by integrating the data sets 
from omic-studies as well as data from those reported in literature has largely been lacking. In the present study 
an integrative analysis of AVNFH associated SNPs, transcriptomic data sets of bone and cartilage, proteomic 
data sets and metabolomic data have been carried out. The data is analysed using cytoscape and binned into 
different pathways using its plugin ClueGO. The SNP data was validated by literature search for experimentally 
verified effects or phenotypes. The deficiency of vitamins/cofactors like  B6,  B12 and Folate and its implications for 
enzyme activity concomitant with deregulation of metabolic pathways has been analysed. The implications of the 
deficiency of these vitamins has been analysed in the light of transcriptomic and proteomic data obtained from 
cartilage or bone from patients and animal models. Further, the SNP data, transcriptomic data and proteomic 
data have been integrated with Vitamin-cofactor enzyme data. The role of SNPs, transcriptomic, proteomic and 
metabolomic data and its role in osteoblast, osteoclast and cartilage biology, their function as well as its implica-
tions for AVNFH has been discussed. The data analysis shows deregulation of multiple pathways consistent with 
the multi-systemic nature of AVNFH. In addition, the genes from integrative analysis common to at least two 
data sets were analysed using DisGeNET. The results show the involvement of these genes with various diseases. 
These diseases are risk factors associated with AVNFH. Further, we validated the role of elevated homocysteine 
on MSC differentiation to osteoblast and mineralization. We also show that RANKL is elevated in the AVNFH 
patients. Using literature mining we show elevated homocysteine, vitamin  B6,  B12, glutathione, N-acetylcysteine, 
CBS and MUT Knock out and knock down modulate RANKL induced osteoclastogenesis. Our analysis provides 
a theoretical basis to understand the disease and raises further questions which could shed light on the disease 
process. This could in turn provide potential biomarkers and newer therapeutic targets in the disease.
Results
SNPs associated with AVNFH and their functional implication. The SNPs were curated from lit-
erature. A total of 57 Genes harbouring SNPs associated with AVNFH were curated. To evaluate the importance 
of SNPs in the disease an interaction network was generated using cytoscape and pathway annotation analysis 
was carried out using the Plugin ClueGO. The analysis using WikiPathways shows that the genes with SNPs 
associated with AVNFH are binned into Vitamin  B12 metabolism, Folate metabolism, TGFβ signalling, matrix 
metallo proteases, Clotting and coagulation, HIF-1 pathway, angiogenesis, Endochondral ossification etc. The 
Reactome pathway binned genes into vacuolar pathway, matrix metallo proteinases, VEGF and purine metabo-
lism. The KEGG pathway binned genes into Coagulation cascade, Fluid shear stress and atherosclerosis, HIF-1 
pathway, VEGF signalling and AGE/RAGE pathway (Fig. 1A–C, Supplementary Data S1). Further, to evaluate 
the functional implication of SNPs in genes associated with AVNFH, we manually curated the experimentally 
verified SNPs with demonstrated impaired function from literature. Of the 57 curated genes harbouring SNPs 
associated with AVNFH, 26 genes harbouring 38 SNPs were found to have experimentally validated functional 
consequences. These SNPs were found to be associated with elevated levels of homocysteine, osteoclastogenesis 
and vasoconstriction. The summary of the genes involved in these processes are provided in Fig. 1D.
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Figure 1.  Pathway annotation analysis and functional implications of AVNFH SNP genes. (A) WikiPathways 
showing involvement of Endochondral Ossification, Angiogenesis, Differentiation pathway, Vitamin  B12, Folate 
metabolism, Blood clotting, Complement and coagulation cascade. (B) KEGG pathways showing fluid shear 
stress and atherosclerosis. (C) Reactome pathways showing VEGF ligand–receptor interactions. (D) Functional 
implications of AVNFH SNPs ascertained from literature (References are provided under supplementary 
references S7).
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Figure 1.  (continued)
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Transcriptomic analysis of AVNFH cartilage shows deregulation in multiple pathways. Tran-
scriptomic analysis was carried out on differential gene expression data sets from AVNFH patient cartilage 
compared to that of controls (GSE74089). The genes with an adjusted P. value of ≤ 0.05 were selected for analysis 
using cytoscape. The genes are subsequently binned into pathways using the plugin ClueGO. The results of anal-
ysis using KEGG shows deregulation of signalling and metabolic pathways having significant term P. value like 
alanine aspartate and glutamate metabolism, glycolysis/gluconeogenesis, methionine and cysteine metabolism, 
 B6,  B12 and Folate (Water soluble vitamin), alcoholism, estrogen pathway etc. (Supplementary Data S2). Analysis 
using WikiPathways shows deregulation of pathways like Tryptophan and histidine catabolism, RANKL/RANK 
signalling Pathway, endochondral ossification, Hematopoietic Stem Cell Differentiation, adipogenesis, Folate-
Alcohol and Cancer Pathway, Iron metabolism, Blood Clotting Cascade and Folate Metabolism (Supplementary 
Data S2). Analysis using Reactome pathways shows deregulation of pathways like Metabolism of water soluble 
vitamins and cofactors, Metabolism of amino acids and derivatives, Phase II conjugation. Regulation of HIF by 
oxygen, signalling by VEGF, Collagen degradation, etc. (Supplementary Data S2). Further, subnetwork analysis 
for Reactome pathways was carried out using Reactome pathways browser (Supplementary Figures S7.1 and 
S7.3). Subnetwork analysis of water soluble vitamins and cofactors shows enrichment of Metabolism of folate 
and pterines, vitamin  B6 activation to pyridoxal phosphate, Cobalamin  (B12) transport and metabolism as well as 
(Fig. 2A–C). Phase II conjugation of compounds showing methylation pathway (Fig. 2D). Subnetwork analysis 
of metabolism of amino acids and derivatives shows enrichment of degradation of cysteine and homocysteine 
pathways, choline catabolism (Fig. 2E,F). The changes in gene expression in various deregulated pathways has 
been analysed for relevance for various metabolic pathways. The deregulation of  B12,  B6, Folate and Choline 
metabolism had major implications for the degradation of cysteine and homocysteine pathway as well as meth-
ylation reaction. The results are summarised in Fig. 2G.
Proteomic analysis of AVNFH Bone shows deregulation in multiple pathways. Proteomic func-
tional analysis was carried out using published dataset for bone tissue affected with AVNFH compared to healthy 
 controls26. The dataset showed 128 significantly upregulated proteins and 52 significantly downregulated pro-
teins. The proteins with significant changes in the levels of expression were used for pathway annotation analysis 
using ClueGO a plugin of Cytoscape. Analysis using Reactome pathways binned the proteins into pathways 
involving—defects in cobalamin  (B12) metabolism, Platelet degranulation, scavenging of Heme from plasma, 
Defective AMN causes hereditary megaloblastic anemia, and Glycolysis pathways (Fig.  3A and Supplemen-
tary Data S3). Analysis using WikiPathways binned the proteins into pathways involving Cori cycle, Selenium 
micronutrient network, Vitamin  B12 metabolism, Folate metabolism etc. (Fig. 3B and Supplementary Data S3). 
Analysis using KEGG pathways binned the proteins into pathways involving Complement and coagulation cas-
cades, Glycolysis/ Gluconeogenesis, inositol phosphate metabolism etc. (Fig. 3C and Supplementary Data S3).
Metabolomic studies on AVNFH shows changes in critical metabolites involved in bone biol-
ogy. From our previous study using plasma from AVNFH patient compared to age and gender matched con-
trol we have shown elevated levels of metabolites belonging to methionine-homocysteine pathway concomitant 
with a reduction in  B6,  B12 and  betaine1. Metabolites belonging to polyamine and urea pathway was also found 
to be  deregulated1. Metabolomics of plasma of AVNFH showed 48 differentially regulated  metabolites23 while 
that of bone trabeculae showed 53 differentially regulated  metabolites25. Pathway annotation analysis of these 
metabolites belonging to individual cohorts were carried out using  MetaboAnalyst30. The published metabo-
lomic data from bone trabeculae shows changes in aminoacid metabolism, purine and pyrimidine metabolism, 
Steroid, thymine and quinone  metabolism25. The results of MetaboAnalyst are provided in Fig. 3D. Different 
metabolites influence bone biology by modulating osteoblast and osteoclast differentiation and their function.
Low levels of vitamin  B6,  B12 and folate or defects in expression of genes that maintain nor-
mal physiological levels of vitamins affect activity of different enzymes belonging to multiple 
metabolic pathways. Data analysis from published Transcriptomic, proteomic and metabolomic data was 
used to arrive at the cofactors that are deregulated in AVNFH. The data from published literature involving 
cofactors and their respective  enzymes31 were used to understand the role of deficiency in cofactors in AVNFH 
 (B6,  B12, Folate). An interaction network of the cofactors and the enzymes were generated and pathway annota-
tion analysis was carried out using ClueGO. The results of this analysis for  B6,  B12, Folate shows enrichment in 
amino acid metabolism, Fatty acid and steroid metabolism, taurine and hypotaurine metabolism, one carbon 
metabolism, cysteine and homocysteine metabolism, selenocysteine metabolism, glycogen and glucose metabo-
lism (Fig. 4A–C and Supplementary Data S4). Subsequently, to evaluate if the enzymes which uses cofactors 
like  B6,  B12, folate are deregulated in AVNFH, we imported the gene expression or protein expression data sets 
into the enzyme-cofactor interaction network. Many of the enzymes belonging to the enzyme-cofactor network 
were found to be upregulated in AVNFH and the genes were subsequently binned into pathways. The analysis 
also showed that though the enzymes were upregulated in AVNFH the dysfunction might mainly stem from 
deficiency of the cofactors (Fig. 4D).
RANKL induced osteoclastogenesis shows changes in the expression levels of genes belong-
ing to choline metabolism and iron metabolism. Homocysteine induces RANKL expression and 
secretion in osteoblasts and synovial  fibroblasts32. In addition, SNPs in RANKL and OPG are found to be asso-
ciated with  AVNFH33. Transcriptomic analysis also shows enrichment of genes belonging to RANK-RANKL 
signaling (Fig.  2H). Hence, we analyzed transcriptomics, studying the role of RANKL in osteoclastogenesis. 
The evidence for increased osteoclastogenesis is also reiterated by Micro-Raman spectroscopy, ultrastructural 
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Figure 2.  Pathway annotation analysis of AVNFH patient cartilage transcriptomics and RANKL induced 
osteoclastogenesis transcriptomics. (A–C) Metabolism of water soluble vitamins and cofactors pathway sub networks 
showing differentially regulated genes belonging to (A) folate metabolism, (B) vitamin  B6, (C) vitamin  B12. (D) Phase II 
conjugation of compounds sub network showing methylation pathway. (E,F) Metabolism of amino acids and derivatives 
sub networks showing (E) degradation of cysteine and Homocysteine pathway and (F) choline catabolism pathway 
(red—upregulated genes; blue—downregulated genes). (G) Summary of findings showing defective vitamin metabolism 
could lead to Homocysteine accumulation. (H) RANKL/RANK signaling in AVNFH transcriptomics. (I) Iron uptake and 
transport pathway in RANKL induced osteoclastogenesis transcriptomics.
7
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18099  | https://doi.org/10.1038/s41598-020-75197-0
www.nature.com/scientificreports/
Figure 3.  Pathway annotation analysis of AVNFH patient bone tissue proteomics. (A) Reactome pathways 
showing defects in Cobalamin metabolism, Scavenging heme from plasma, Megaloblastic anemia, Platelet 
degranulation pathways. (B) WikiPathways showing vitamin  B12 and folate metabolism. (C) KEGG pathways 
showing complement and coagulation cascade pathway. (D) Pathway annotation analysis of AVNFH 
metabolomics showing significant pathways of patient targeted plasma metabolomics, significant pathways of 
patient non targeted plasma metabolomics and significant pathways of patient bone trabeculae metabolomics.
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Figure 4.  Vitamin  B6,  B12 and folate cofactor dependent proteins network and pathway annotation analysis. 
(A) KEGG pathways showing one carbon pool by folate, Cysteine and Methionine metabolism, Taurine 
and Hypotaurine metabolism. (B) Reactome pathways showing degradation of cysteine and homocysteine 
pathway. (C) WikiPathways showing Vitamin  B12, folate, Transulfuration and one carbon metabolism pathway. 
(D) Overlay of gene expression values onto cofactor—protein pathways showing upregulated genes (Red—
upregulated).
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studies, histopathology and IHC from previous  studies1. Analysis of RANKL induced osteoclastogenesis shows 
enrichment of genes belonging to Choline metabolism, Heme degradation, single carbon metabolism and Iron 
metabolism (Fig. 2I and Supplementary Data S5). SNPs in genes implicated in Iron metabolism is associated 
with AVNFH. More so, many diseases like sickle cell anemia, beta-thalassemia and hemochromatosis are associ-
ated with AVNFH. All these diseases show iron overload and increased osteoclastogenesis or presence of osteo-
clast markers in the  serum9,10.
Integrative analysis of SNPs associated with AVNFH, Transcriptomic and Proteomic data as 
well as Cofactor-Enzyme data sets shows common pathways critical for progression of AVNFH 
which is also reflected in histopathology, IHC, Micro-Raman spectroscopy, CT and MRI of 
AVNFH patients or animal models. The integrated network was obtained by merging individual net-
works of AVNFH SNPs, Proteomic, transcriptomic, and cofactor—protein networks using cytoscape. The net-
work centrality analysis gave the degree, closeness and betweenness scores of individual nodes. 123 nodes had 
degree 2 (the genes were common in at least two data sets used). Two of the nodes, CBS and MUT had degree 
3. Defective MUT and CBS due to Vitamin  B12 and  B6 deficiency respectively leads to accumulation of Methyl 
malonic acid and Homocysteine which stimulate  osteoclastogenesis34,35 (Fig. 5A and Supplementary Data S6). 
These 125 hub nodes were used for ClueGO functional analyses. The integrative pathway annotation analysis 
with WikiPathways shows changes in Cori cycle, one carbon metabolism, TGFβ signaling, trans-sulfuration 
pathway, vitamin metabolism etc., (Fig. 5B and Supplementary Data S6). Reactome shows changes in amino acid 
metabolism, glucose metabolism, platelet degranulation, Iron and heme metabolism, single carbon metabolism, 
megaloblastic anemia, platelet degranulation etc., (Fig. 5C and Supplementary Data S6). Pathway annotation 
analysis using KEGG shows perturbations in amino acid metabolism including cysteine and methionine metab-
olism, HIF signaling, AGE-RAGE signaling pathway etc., (Fig. 5D and Supplementary Data S6). Further, we 
also looked at the expression levels of genes belonging to different modules like elevated homocysteine, hypoxia, 
osteoclastogenesis, endochondral ossification as well as coagulation and vasoconstriction. The expression levels 
of these genes as well as their statistical significance are provided from transcriptomic analysis (Fig. 5E). These 
genes could be of potential use for any future investigation to address the role of different modules in AVNFH.
In addition, the data from AVNFH patients and animal model systems for MRI, CT, Histopathology, IHC 
and Micro-Raman Spectroscopy of bone was correlated with molecular signatures obtained from –Omic analy-
sis. Micro-Raman spectroscopy of human AVNFH bone and piglet AVNFH model showed reduced mineral 
matrix ratio and increased carbonate to phosphate ratio indicative of increased osteoclastogenesis and decreased 
osteoblast function (Supplementary Table S7.5 and references there in). The molecular signatures of increased 
osteoclastogenesis and homocysteine mediated inhibition of mineralization by osteoblast correlate with these 
results (Supplementary Table S7.5 and references there in). Histopathology of AVNFH bone reveals increased 
cement lines, empty lacunae and marrow calcification, which correlate with the molecular features like osteo-
clastogenesis, endochondral ossification and elevated homocysteine (Supplementary Table S7.5 and references 
there in). Consistent with this IHC studies have revealed changes in RANK, RANKL, Osteocalcein, BMP2 etc. 
which are indicative of bone remodeling, increased osteoclast and osteoblast activity (Supplementary Table S7.5 
and references there in). MRI-BOLD of AVNFH patients show significant changes in oxygen content of arterial 
and venous blood. MRI data also shows changes in velocity of blood flow (Supplementary Table S7.5 and refer-
ences there in). Histopathology shows coagulation and vasoconstriction in AVNFH patients (Supplementary 
Table S7.5 and references there in). The molecular signature of increased coagulation, atherosclerosis, platelet 
degranulation, elevated homocysteine, Von Willebrand factor and microparticles correlate with the findings of 
MRI and Histopathology (Supplementary Table S7.5 and references there in). The coagulation process also leads 
to hypoxia (Supplementary Table S7.5 and references there in) which corroborate with increased HIF-1α and 
VEGF staining in AVNFH bone using IHC (Supplementary Table S7.5 and references there in). The SNP and 
transcriptomic data also bins genes into hypoxia signaling pathway in AVNFH.
Over all the integrative analysis not only agrees with the results of individual pathways but also provided 
important pathways that are common to AVNFH from different studies. Our results show the enrichment of 
genes in pathways that describe the symptoms and its associations with AVNFH such as elevation in homocyst-
eine, coagulation, hypoxia, Vasoconstriction, endochondral ossification, osteoclastogenesis and their eventual 
effect (Fig. 6). Above all, the observations of Micro-Raman spectroscopy, Histopathology, CT, IHC and MRI 
studies correlate with the molecular signatures obtained from the Omic analysis. A summary of the role of dif-
ferent pathways and possible processes which they influence in AVNFH is provided (Fig. 7 and Supplementary 
Table S7.4). 
Analysis of 125 genes common to at least two data sets from Integrative analysis reveals their 
association with many diseases which are risk factors for AVNFH. The integrative analysis using 
data sets from SNP, Transcriptomics, proteomics and enzyme-cofactor data showed 125 genes to be common 
to at least two data sets. These 125 genes were used for further analysis for diseases enrichment employing 
DisGeNET and Rare diseases gene set libraries from Enrichr. The top 40 genes were found to be associated 
with various diseases (Fig. 8A,B). These diseases include Microangiopathy, bone necrosis, aneurysm, pulmo-
nary embolism, diabetic angiopathies, overweight, thrombophilia, hyperthyroidism, cerebrovascular events, 
anemia, sickle cell eclampsia, nephrotic syndrome, homocysteinemia, Kidney diseases, hemochromatosis and 
other diseases (Fig. 8A,B). Metabolomic analysis of perfused renal cortex samples from diabetic kidney disease 
rat models showed derangement of metabolites belonging to methionine  pathway36. Further, by literature min-
ing we could show that most of the diseases found using DisGeNET analysis were found to be risk factors for 
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Figure 5.  Integration of AVNFH omic analyses: (A) Integrated network of AVNFH transcriptomics, Proteomics, 
SNP genes and cofactor—protein network. Red nodes are hub genes, among which CBS and MUT showed 
highest network centrality scores. (B) WikiPathways annotation analysis of hub genes showing Vitamin  B12, 
folate metabolism, transulfuration and one carbon metabolism. (C) Reactome pathways showing Iron uptake, 
transferrin endocytosis, scavenging heme from plasma, megaloblastic anemia pathways. (D) KEGG pathways 
showing HIF signaling, cysteine and methionine metabolism, one carbon pool by folate pathways. (E) Gene 
expression values of genes belonging to different modules like elevated homocysteine, hypoxia, osteoclastogenesis, 
endochondral ossification as well as coagulation and vasoconstriction from transcriptomics analysis.
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AVNFH (Fig. 8A,B). Taken together our analysis with molecular signatures could predict the diseases which are 
risk factors associated with AVNFH.
Validation of homocysteine and osteoclastogenesis (RANKL) module by experiments and lit-
erature mining. The analysis carried out in this study shows SNP in MTHFR, low  B6,  B12 and Folate as 
well as factors like Alcoholism by literature mining to be associated with AVNFH. The data analysis using SNP, 
transcriptomic, proteomic and metabolomic and the enzyme-cofactor data also showed involvement of elevated 
homocysteine in AVNFH (Fig. 6). Since the etiological, genetic and metabolic factors lead to elevated levels of 
homocysteine, we treated Mesenchymal Stem Cells with basal medium as well as osteogenic medium with and 
without homocysteine. MSC treated with homocysteine led to a significant reduction in ALP staining indicative 
of reduced osteoblastogenesis (Fig. 8C,D). Further mineralization assay using alizarin red showed significantly 
reduced mineralization in homocysteine treated sets compared to controls (Fig. 8E,F).
Systems analysis using the data sets shows osteoclastogenesis as one of the modules modulating the disease 
process (Fig. 6). RANKL is involved in osteoclastogenesis. Since SNP in RANKL is associated with AVNFH 
and transcriptomic analysis of AVNFH showed RANK-RANKL signaling, we estimated the level of RANKL 
in AVNFH patients who had high  homocysteine1 compared to controls. RANKL was found to be significantly 
elevated in AVNFH patients compared to controls (Fig. 8G). Our integrative analysis showed CBS and MUT 
to be common to three of the four data sets used. Hence, we carried out literature mining to see if knock 
down, knock out, cofactor depletion or supplementing downstream products of CBS could modulate RANKL 
induced osteoclastogenesis. The results shows that depletion of  B6 and  B12 significantly augmented RANKL 
induced osteoclastogenesis (Supplementary Table S7.7). RANKL treatment in presence of siRNA which knock 
down CBS also significantly increased osteoclastogenesis (Supplementary Table S7.7). Similarly RANKL in pres-
ence of homocysteine significantly elevated osteoclastogenesis (Supplementary Table S7.7). Further, RANKL 
induced osteoclastogenesis could be inhibited by treatment with glutathione (Supplementary Table S7.7). Mice 
model of CBS KO exhibited hyperhomocystenemia and osteoporosis. Supplementation with N-Acetylcysteine 
was shown to decrease osteoclastogenesis and increase bone mass (Supplementary Table S7.7). Mice model of 
MUT KO exhibited hematological abnormalities like mild macrocytic anemia and low bone mineral density 
Figure 6.  Modules of salient features of AVNFH addressed in our study by analysing various omic data and 
their integration with published results of histopathology, IHC, MRI, CT and Micro-Raman Spectroscopy. 
(A) Endochondral ossification, (B) osteoclastogenesis, (C) hypoxia, (D) coagulation and vasoconstriction, (E) 
elevation of homocysteine.
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(Supplementary Table S7.7). Depletion of Vitamin  B12 was shown to stimulate osteoclastogenesis by way of 
increasing homocysteine and methyl malonic acid (Supplementary Table S7.7).
Taken together our –Omic analysis results as well as integrative analysis using different data sets shows CBS 
and MUT to be associated with the disease. CBS and MUT, for their activity require  B6 and  B12 as cofactors 
respectively, which is present in low levels in the patients. Knock down, knock out or cofactor depletion  (B6, 
 B12) lead to elevated levels of homocysteine and methyl malonic acid which modulate MSC differentiation to 
osteoblasts, macrophage differentiation to osteoclasts as well as their function with potential implications for 
the disease.
Discussion
SNPs associated with AVNFH are collected from the literature. Network of SNPs associated with AVNFH was 
generated using Cytoscape and the SNPs in genes were binned into pathways. Furthermore, the functional impli-
cations of SNPs that were validated experimentally was collected from literature and its implication for AVNFH 
was discerned. The SNPs were associated with elevated homocysteine, hypoxia, osteoclastogenesis or coagulation 
and vasoconstriction. Transcriptomic analysis binned the genes into signaling pathways, metabolic pathways and 
other pathways that has implication for bone biology and disease manifestation. Proteomic data collected from 
the literature shows changes in pathways like  B12 and coagulation which has implications for disease process. The 
cofactor-enzyme network conjured pathways that are deregulated in the disease, which has major implications 
for disease progression. The integrated analysis of SNP, Transcriptomic, proteomic and cofactor network shows 
common pathways that are deregulated in the disease that are very critical to the disease process. Analysis of the 
genes that are common to at least two data sets in the integrative analysis using DisGeNET showed association 
with multiple diseases. Interestingly cross validation using literature mining showed that these diseases are risk 
factors associated with AVNFH. In order to validate the prediction of a role for elevated homocysteine in vitro 
studies were carried out using MSC. Experimental validation of the role of homocysteine shows impaired MSC 
differentiation to osteoblasts and their function. In addition to this we also probed into the role of RANKL in 
AVNFH by measuring the levels of RANKL in our patient cohort. Subsequently the factors that modulate RANKL 
induced osteoclastogenesis was validated by literature mining. Our analysis showed elevated levels of RANKL 
in AVNFH patients. Using literature mining we show that RANKL induced osteoclastogenesis is augmented 
by homocysteine, depletion of  B6 and  B12, knock down/knock out of CBS or MUT. RANKL induced osteoclas-
togenesis could be attenuated by supplementation of glutathione or N-Acetylcysteine in CBS KO mice. Taken 
Figure 7.  AVNFH as a multi systemic disease. (A) Different processes implicated in AVNFH from literature. 
(B) Possible pathogenesis model of AVNFH constructed on the basis of biochemical, omics, biophysical results 
and literature mining (references are provided in supplementary references S7).
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Figure 8.  (A) DisGeNet clustergram showing enriched disease terms and associated genes. Numbers below show 
the reference which shows association of the disease with AVNFH. (B) Rare diseases GeneRIF genelists clustergram 
showing enriched disease terms and associated genes. Numbers below show the reference which shows association of 
the disease with AVNFH. (C) ALP activity staining showing reduced ALP activity (ALP staining) during osteogenic 
differentiation, in presence of Homocysteine. (D) ALP activity Staining quantification using ImageJ (Version: 1.46r 
URL: https ://image j.nih.gov/ij/) (P. value = 0.03) (E) Alizarin Red S staining showing reduced matrix mineralization 
during osteogenic differentiation in presence of Homocysteine. (F) Alizarin red staining quantification (P. value = 0.02). 
(G) Box plot showing elevated levels of RANKL in AVNFH patients (with high homocysteine, Narayanan et al. 2017) 
compared to healthy controls (P. value = 0.0074). P. value ≤ 0.05 was considered to be significant.
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together the analysis recapitulates the observed processes associated with the disease which could be validated 
by experiments and literature mining.
Previous studies have shown significant association of elevated levels of homocysteine with  AVNFH1. The 
analyzed data at the level of SNPs, Transcriptomic, proteomic, metabolomics or their integrative analysis shows 
involvement of cysteine and methionine pathway, one carbon metabolism,  B12 metabolism,  B6 and folate metabo-
lism, megaloblastic anemia etc. In addition, alcoholism which is a risk factor for AVNFH also leads to reduced 
levels of  B12 and increased levels of  homocysteine37. Our previous studies have shown lower levels of hemoglobin 
in AVNFH patients compared to age and gender matched  controls1. However, whether the reduced hemoglobin 
correlated with megaloblastic anemia was not confirmed. Homocysteine has implications for bone biology as it 
remodels osteoblastogenesis, osteoclastogenesis and their  function38,39. Homocysteine is also an inflammatory 
molecule and induces inflammatory response in the macrophages. Homocysteine is known to inhibit the activity 
of NOS. NOS is an important enzyme which is essential for vascular  function40. Inhibition of NOS also leads to 
increased  osteoclastogenesis41. Homocysteine also modulates blood  coagulation42. In addition, homocysteine is 
known to induce  ROS43.  B6 is an important vitamin which is a cofactor for cystathionine beta synthase involved 
in the synthesis of cysteine and thus  glutathione44. Reduced levels of  B6 not only contribute to increased homo-
cysteine but also to decreased cysteine, which is essential for the synthesis of glutathione. Our integrative analysis 
shows CBS as a key enzyme in the transsulfuration pathway which might be involved in AVNFH. Thus SNPs or 
vitamins like  B6,  B12 and folate or alcoholism might modulate the levels of homocysteine in different populations 
which in turn influences multiple pathways in the progression of AVNFH.
AVNFH has also been associated with coagulation disorders. Consistent with this SNP analysis Using the 
Plugin ClueGO binned genes into blood clotting cascade, complement and coagulation cascade. ClueGO analysis 
of network generated with the SNP containing genes along with first neighbors show that the genes are binned 
into Platelet degranulation pathway. ClueGO analysis of Network generated from Proteomic data sets shows genes 
binned into platelet degranulation, complement and coagulation cascade. Platelet degranulation is an important 
process in coagulation  pathway45. Previous studies have shown an association of homocysteine with  AVNFH1. 
Homocysteine potentiate ADP induced platelet degranulation and  coagulation46. Increased Von Willebrand 
factor which is involved in coagulation process is also associated with  AVNFH47. SNP in Collagen associated 
with AVNFH is shown to induce platelet  activation48,49. In addition, microparticles in blood are associated with 
the  disease16. The association of coagulation and vasoconstriction is also supported by histopathology and MRI-
BOLD as well as blood velocity  studies50. Hence multiple factors at the genetic, transcriptomic, metabolomic or 
at the level of cofactors might contribute to coagulation cascade which is associated with AVNFH.
Previous studies using Micro-Raman Spectroscopy shows increased carbonate to phosphate and decreased 
mineral matric ratio in AVNFH bone from both patients and piglet  model1,11. CT scan shows reduced Houns field 
unit an indication of reduced bone  density1. The data is suggestive of increased osteoclast and decreased osteo-
blast function. The increased resorption of bone is ascribed to increased osteoclastogenesis and its  function51. 
In addition, AVNFH bone shows increased bone turnover as observed in the Immunohistochemistry (IHC) 
for  osteocalcein1. Homocysteine is shown to modulate osteoclastogenesis. Studies have reiterated a role for 
homocysteine in osteoblast induced osteoclastogenesis by way of RANKL expression and  secretion32.  B12 and  B6 
depleted media are shown to augment the differentiation of macrophages to  osteoclasts52. Our AVNFH patient 
cohort show elevated level of RANKL in plasma. IHC of patient bone also shows increased RANK, RANKL 
 staining13. More so, Iron sequestration is an important event in  osteoclastogenesis53. Consistent with these facts, 
RANKL induced osteoclastogenesis shows upregulation of genes involved in iron  metabolism54. Knocking down 
genes involved in endosome acidification was shown to inhibit  osteoclastogenesis55. SNP analysis shows HIF-1 
signaling pathway and VEGF signaling pathway are associated with hypoxia. SNP and Transcriptomic analysis 
shows regulation of gene expression by HIF-1α. Traumatic AVNFH is associated with hypoxia as seen in animal 
model of  AVNFH56. In addition, the microparticles in blood associated with ANVFH is proposed to clog capillar-
ies inducing hypoxic  conditions16,17. Consistent with this immuno-histochemistry shows increased HIF-1 staining 
in AVNFH  bone15. MRI-BOLD technique also shows changes in the oxygenation of arterial and venous blood in 
AVNFH patients compared to controls (Supplementary Table S7.5 and references there in). Hypoxia is involved 
in osteoclastogenesis and lead to bone  resorption57. Transcriptomic analysis shows TGFβ signaling pathway 
is important for osteoclastogenesis and TGFβ Receptor knock out inhibits  osteoclastogenesis58. Thus multiple 
signaling pathways together might provide conditions favorable to osteoclastogenesis and bone degradation.
Homocysteine is shown to inhibit the expression of  LOX159 which is involved in collagen cross linking. 
Previous studies have shown Homocysteine inhibit the differentiation of mesenchymal stem cells (MSC) into 
 osteoblasts60. However, contradictory results are obtained in case of homocysteine induced  mineralization61. 
Increased iron also inhibit differentiation of MSC into  osteoblasts62. Consistent with this a role for iron is con-
ceived in osteoclastogenesis, osteoblastogenesis and their function. Iron overload diseases like sickle cell anemia, 
beta-thalassemia and hemochromatosis are risk factors for AVNFH. The histopathological changes also report 
empty lacunae in bone, indicative of absence of osteoblasts, reverse cement lines, marrow calcification etc., 
which shows deregulation and imbalance in osteoblast and osteoclast  function1. The different pathways might 
act in concert to impede MSC differentiation into osteoblasts and promote differentiation of macrophages into 
osteoclast as well as modulate their function.
Endochondral ossification is a process where cartilage is replaced by  bone63. Network analysis of SNPs associ-
ated with AVNFH and transcriptomic analysis of AVNFH cartilage shows binning of genes involved in endo-
chondral ossification pathway. Cartilage in AVNFH shows hypertrophy and death in  AVNFH64.
Treatment with Bisphosphonate is the standard care treatment for  AVNFH65. Bisphosphonate acts at mul-
tiple levels by inhibiting osteoclastogenesis and preventing coagulation by inhibiting platelet  degranulation66. 
Bisphosphonate also helps in increasing  mineralization65. However, in the absence of osteoclastogenesis, this 
might lead to woven bone formation which might hamper bone  strength67.
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In the present study, analysis of genes common to at least two data sets using DisGeNET showed association 
with various diseases. Validation using literature showed these diseases are risk factors associated with AVNFH 
(Supplementary Table S7.6 and the references there in). However, in the diseases which are risk factors for 
AVNFH, if the associated genes of our DisGeNET analysis are involved in disease process leading to AVNFH 
remain to be experimentally validated. Analysis of SNPs, the expression levels of these genes or levels of cofactors 
required for their activity might shed light on their role in progression to AVNFH.
Further, our work shows that elevated levels of homocysteine ensue, as a consequence of multiple factors like 
SNP on MTHFR, reduced  B6,  B12 or folate. We show that elevated Homocysteine leads to impairment of MSC 
differentiation into osteoblasts and inhibit their mineralization function. Previous studies have also shown that 
homocysteine causes apoptosis in mesenchymal stem  cells60. Transcriptomic analysis shows RANK-RANKL 
signaling in AVNFH. We show that RANKL is elevated in the plasma of AVNFH patients. Literature mining 
shows that RANKL induced osteoclastogenesis is augmented by depletion of  B6 or  B12 in media. Knock down 
of CBS which came up as a critical gene in three of the four data set in our integrated analysis increased osteo-
clastogenesis, while supplementation of glutathione was shown to inhibit  osteoclastogenesis68. CBS KO mice 
showed increased osteoclastogenesis and osteoporosis which could be mitigated by supplementation of N-acetyl 
cysteine. Similarly, MUT KO mice exhibited anemia and reduced bone  density69.
Overall the results of our analysis show that the molecular signatures of SNPs, transcriptomics, proteomic, 
metabolomic and cofactor-enzyme data captures the tenets of pathophysiology and symptom associated changes 
in bone biology, biophysical, immunohistochemical and histopathological changes characteristic of the disease. 
However, due caution should be exercised as the work with human and animal model systems only can be used 
to reiterate the conserved pathways as the animal models may not be truly representative of AVNFH in humans. 
This work also paves way for a deeper insight into the role of homocysteine and iron metabolism in the patho-
physiology of AVNFH. The work also shows various diseases which are risk factors associated with AVNFH, 
and raises additional questions on the potential role or association of different genes in AVNFH. The work also 
helps to delineate the potential benefits of treatment with bisphosphonate as it interferes with ostoclastogenesis 
and coagulation process associated with AVNFH.
Conclusions
Our integrative analysis points to the contribution of multiple factors like hypoxia, coagulopathy, deficiency of 
vitamins like  B6,  B12, folate, high homocysteine, osteoblastogenesis, osteoclastogenesis, endochondral ossifica-
tion etc., in remodeling of AVNFH bone and progression of the disease. The molecular signatures correlate with 
observations like coagulation, hypoxia, decreased osteoblastogenesis, increased osteoclastogenesis and their 
deregulated function in the disease. This in turn complies with previous MRI, biophysical, immunohistochemical 
and histopathological studies of the AVNFH bone. The role of coagulation pathway in the diseases and factors 
that affect it also are evident from the systems analysis of data sets which might contribute indirectly to disease 
process. The work also shows multiple factors like SNPs, Alcoholism, cofactor deficiency or iron overload diseases 
as well as other diseases that could lead to similar environment which might favor disease progression. A role 
for specific genes involved in these diseases which are risk factors for AVNFH remain to be ascertained experi-
mentally. The present work also provides direction where supplementation of vitamins like  B6,  B12 and folate 
might help in management of the disease. The result of our analysis shows AVNFH as a multi-systemic disease.
Material and methods
SNPs associated with AVNFH and functional implication. The SNPs associated with AVNFH were 
obtained from literature. The inclusion criteria were all SNPs that have association with AVNFH/osteonecrosis, 
while all those that did not show any association in a particular study with AVNFH/osteonecrosis were excluded. 
GWAS data for AVNFH/osteonecrosis was also searched and SNPs were included. SNPs which were associated 
only with osteonecrosis other than that of femoral head were excluded. The SNPs were categorised into Exonic, 
which contained the synonymous and non-synonymous SNPs, Intronic in introns, promoters, 3ÚTR and inter-
genic regions. The list of SNPs was binned into pathways using ClueGO 70 plugin of cytoscape for pathway 
annotation 71 and the pathway networks were visualised in Cytoscape. ClueGO uses KEGG, Reactome and 
WikiPathways 72–74 to bin genes into pathways. Further the functional implication of SNPs was discerned by 
literature search for experimentally validated data. For finding experimental validation of SNPs associated with 
AVNFH from literature OMIM data base was searched and search was also carried out with rs ID or name/nota-
tion of genes followed by functional implications or experimental validation. All SNPs with impaired function or 
implications for a function were included while those without any consequence were excluded.
AVNFH gene expression microarray, proteomic and metabolomics data. The gene expression 
microarray study involved a genome wide Gene expression profiling of hip articular cartilage with AVNFH. 
Gene expression microarray data of GEO accession GSE74089 was obtained from Gene Expression  Omnibus75 
(GEO; https ://www.ncbi.nlm.nih.gov/geo/) based on the platform GPL13497 (Agilent-026652 Whole Human 
Genome Microarray 4 × 44 K v2), deposited by Ruiyu  L24. Gene expression profiling of AVNFH articular car-
tilage was carried out by collecting hip articular cartilage specimens from 12 AVNFH patients and 12 healthy 
controls. Microarray data of GEO accession GSE74847 was used which studied RANKL induced osteoclastogen-
esis using RAW 264.7  cells76. The Proteomic data from AVNFH bone tissue compared to healthy control bone 
tissue was used from a published  dataset26. Data from three published metabolomic analyses were used for our 
study. Our previous study involving targeted metabolomics of plasma samples from 14 patients compared to 14 
healthy control samples were  used1, a global non-targeted metabolomics of plasma samples from 30 AVNFH 
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patients compared to 30 healthy  controls23, and a bone trabecular metabolomics study of 28 patients compared 
to 20  controls25.
Differential gene expression analysis and data pre-processing. The GEO2R web tool was used to 
define two groups of samples namely (necrotic femoral head) ‘NFH’ and ‘Control’, and to perform Differential 
Gene Expression  analysis77. The GEO2R tool uses the GEO-query and limma R packages from the Bioconduc-
tor project to compare the original processed data tables supplied by the submitter. The GEOquery R package 
parses GEO data into R data structures that can be used by other R  packages77. The limma (Linear Models for 
Microarray Analysis) R package has statistical tests for identifying differentially expressed  genes78. The GEO2R 
tool was used to define groups such that the logFC gave fold change of NFH group with respect to Control group. 
i.e., a positive logFC implied upregulation of gene in NFH group and negative logFC implied downregulation 
in NFH group.
The adjusted p. Value from the Limma package was used to identify genes that were significantly differentially 
expressed between the Control and NFH patient sample. The Value adjustments, also called multiple-testing 
corrections, attempt to correct for the occurrence of false positive results. The Benjamini & Hochberg false 
discovery rate  method79 was used for adjustment of the microarray data and provide a good balance between 
discovery of statistically significant genes and limitation of false positives. Significant differentially expressed 
genes of Adjusted P. Value ≤ 0.05 were used for this study. Significant changes in the proteomic and metabolomics 
analyses were obtained from the respective published datasets.
ClueGO and metaboanalyst pathway annotation analyses. The ClueGO plugin of Cytoscape was 
used for pathway annotation  analysis70,71. ClueGo can perform Enrichment (right-sided hypergeometric test), 
Depletion (left-sided hypergeometric test) or Enrichment/Depletion (two-sided hypergeometric test). We have 
used Enrichment/Depletion (two-sided hypergeometric test) for our analyses which are  recommended80. The 
significant differentially expressed genes were used for querying Reactome, KEGG and  WikiPathways72–74 data-
bases for pathway functional analyses. The pathway terms showing term P. Value ≤ 0.05 were considered for fur-
ther analysis. Significant pathways of interest were used for creating subnetworks containing specific daughter 
pathways with genes involved to understand differential gene expression and predict mechanism of derangement 
of metabolic pathways. Cytoscape tools were used to generate specific pathway networks from global pathways.
Cluepedia plugin of Cytoscape was used to add all genes present in all the pathway terms of the  network81. 
Subnetworks of pathways showing pathway terms and their associated genes were created. logFC data of genes 
was then imported into cytoscape and was overlaid with the subnetwork. MetaboAnalyst tool was used to bin 
significant metabolites into KEGG  Pathways30.
Vitamin  B6, vitamin  B12 and folate cofactor: protein interaction network. Since Vitamin  B6,  B12 
and Folate cofactors are implicated in  AVNFH1,82, an interaction network involving these cofactors and respec-
tive proteins was created and visualised in  Cytoscape71. We have created this network based on the published 
dataset involving cofactors–protein interaction network used for understanding relation between human nutri-
tion and  diseases31. The created Vitamin  B6,  B12 and Folate cofactors – protein network was used for ClueGo 
analyses.
Integratedomic network construction and network centrality analyses. Networks for individual 
analyses involving AVNFH SNPs, Proteomic, Transcriptomics and Cofactor-protein networks were created 
using Cytoscape. Next these individual networks were merged in Cytoscape to obtain an integrated network. 
To understand common key nodes in AVNFH, network centrality analysis was carried out using CytoNCA 
plugin of Cytoscape 83. The hub nodes obtained from network centrality analysis was used for further functional 
analyses using ClueGO.
Drug/disease enrichment analyses using Enrichr. The 125 hub nodes from integrated omics network 
with degree 2 and 3 were used to carry out Drug/Disease enrichment analyses. Enrichr web—based tool was 
used to carry out Drug / Disease enrichment analyses 84. We used gene—set libraries from DisGeNet and Rare 
Diseases GeneRIF Gene Lists. DisGeNet is a comprehensive repository of human gene—disease associations. 
Rare Diseases GeneRIF Gene Lists has gene—disease associations based on GeneRIF (Gene Reference into 
Function) to enrich the functional annotation of genes. The enriched terms were sorted using combined score 
ranking after carrying out the enrichment analyses using Enrichr tool.
RANKL ELISA. All the blood samples of AVNFH (n = 5) and controls (n = 7) were procured from patients 
visiting Sri Sathya Sai Institute of Higher Medical Sciences in a de-identified manner by a honest broker as per 
approval of the SSSIHMS institutional bioethics commission (Approval number: SSSIHL/IEC/PSN/BS/2012/05) 
Informed consent was obtained from all subjects and the methods were carried out in “accordance” with the 
approved guidelines and regulations. Plasma samples from healthy control, and AVNFH were frozen at − 80 °C 
until assay was done. Commercial ELISA kits (Peprotech) of human sRANK ligand (Cat. No. 900-M142), were 
used in the study as per manufacturer’s instructions. Dilutions of antibodies were carried out as per manufac-
turers instruction unless otherwise specified. Briefly, 96 well micro-titer plates (Corning Product #3590) were 
coated with capture antibody and incubated overnight at room temperature. Following this, the plate was first 
washed with wash buffer and blocked with block buffer for 1 h at room temperature. Standards and sample dilu-
tions were prepared using the diluent and pipetted into designated wells. Detection antibody was added imme-
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diately into the standards and sample wells and incubated for 2 h at room temperature. After thorough washing, 
Avidin- HRP conjugate was added and incubated for 30 min at room temperature. Finally, ABTS Liquid sub-
strate provided by the manufacturer in the respective kit was added into each well and incubated for 30 min at 
room temperature. Absorbance at 405 nm (reference absorbance 650 nm) was obtained within 30 min of adding 
the stop solution and the results were calculated using a log–log or 4- parameter curve fit. P. value ≤ 0.05 was 
considered significant.
MSC isolation from mice. Animal experiments were approved by the Institutional Animal Ethics Com-
mittee, Indian Institute of Science, Bangalore, India. All animal protocols were performed in accordance with the 
guidelines for care and use of laboratory animals set by Indian National Science Academy. Six to eight -week-old 
CD-1 female mice, weighing 25–28 g, were used for the isolation of BM-MSCs BM-MSCs were isolated as previ-
ously described (PMID: 29760732). Briefly, the mice were sacrificed by cervical dislocation and the femurs and 
tibias were dissected out. The bone marrow was flushed with Dulbecco’s phosphate-buffered solution (DPBS; 
Thermofisher scientific, Waltham, USA). The cell suspension was filtered through a 70 μm cell strainer (BD 
Falcon, USA), and centrifuged at 300×g for 10 min. The cell pellet was suspended in 1 ml MSC culture medium 
composed of Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 
1% penicillin/streptomycin and 2 mM glutamine (all purchased from Thermo Scientific, Waltham, USA). Cells 
were seeded in 35 mm cell culture dishes at a density of 1 × 106 cells/cm2 and incubated in a humidified incuba-
tor at 37 °C, 5%  CO2. After 1 day, nonadherent cells were removed by washing twice with DPBS and fresh MSC 
culture medium was added. The medium was replaced with fresh MSC culture medium every 2 days.
MSC cell culture and osteogenic differentiation. Mouse bone marrow derived Mesenchymal Stem 
Cells (MSCs) were cultured in basal medium (BM) consisting of DMEM (Gibco) supplemented with 10% FBS 
(Gibco), 1% Penicillin –Streptomycin solution (Gibco) and 1% Glutamax (Gibco). Cells were cultured in 4 well 
plates in basal medium till cells reached 70% confluence following which the basal medium was replaced with 
Osteogenic medium (OM) which consisted of basal medium supplemented with Ascorbate—100 µM (Sigma-
Aldrich) and β-glycerophosphate—5 mM (Sigma-Aldrich). During osteogenic differentiation, effect of appro-
priate concentration of Homocysteine—30  µM60 was studied by using DL Homocysteine (Sigma-Aldrich). 
Medium was changed every 3 days.
ALP activity staining and Alizarin Red S staining. Effect of Homocysteine on Alkaline Phosphatase 
activity during osteogenic differentiation was carried out after 7 days of treatment. ALP activity staining was 
carried out by fixing cells with 4% para formaldehyde. After fixation the cells were stained with staining solu-
tion containing Napthol–AS–MS Phosphate—0.4 mg/ml (Sigma-Aldrich), Fast Red TR salt—1 mg/ml (Sigma-
Aldrich), dissolved in Tris-Maleate buffer—30 mM at pH 9, in presence of 0.08% MgCl2 solution. At pH 9, in 
presence of Mg2 + and Alkaline Phosphatase, Napthol–AS–MS Phosphate and Fast Red TR combine to form an 
insoluble Azo red end product.
Effect of Homocysteine on matrix mineralization, was carried out using Alizarin Red S staining to stain 
calcium deposits. After 14 days of treatment, the cells were fixed with 4% para formaldehyde. Then the cells 
were stained with 2% Alizarin Red S solution (Sigma-Aldrich) whose pH was adjusted to 4.2 using ammonium 
hydroxide solution. Alizarin Red S stains calcium deposits to give red colouration.
ALP activity staining and Alizarin staining was quantified using ImageJ software (Version: 1.46r URL: https 
://image j.nih.gov/ij/), by calculating the intensity of the stained area. Data is presented as mean fold change of 
at least 5 sample images from each group. P. Value ≤ 0.05 was considered significant.
Ethics approval. Experiments on humans and the use of human blood samples: We confirm that all experi-
ments were performed in accordance with relevant guidelines and regulations.
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